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Abstract: There is an ever-increasing appreciation for our gut microbiota that plays a crucial role in
the maintenance of health, as well as the development of disease. Probiotics are live bacteria that
are consumed to increase the population of beneficial bacteria and prebiotics are dietary substrates
intended to promote the propagation of beneficial bacteria. In order to optimize the use of probiotics
and prebiotics, a more complete biochemical understanding of the impact that these treatments
have on the community and functioning of the gut microbiota is required. Nucleic acid sequencing
methods can provide highly detailed information on the composition of the microbial communities
but provide less information on the actual function. As bacteria impart much of their influence on
the host through the production of metabolites, there is much to be learned by the application of
metabolomics. The focus of this review is on the use of metabolomics in the study of probiotic and
prebiotic treatments in the context of human clinical trials. Assessment of the current state of this
research will help guide the design of future studies to further elucidate the biochemical mechanism
by which probiotics and prebiotics function and pave the way toward more personalized applications.
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1. Introduction
Research in the area of probiotic and prebiotic interventions has increased exponentially in recent
decades. As defined by the International Scientific Association for Probiotics and Prebiotics, probiotics
are live microorganisms that confer a health benefit on the host when administered in adequate amounts,
whereas prebiotics are substrates that are selectively utilized by host microorganisms conferring a
health benefit [1]. This notion of therapeutic modulation of the gut microbiota is hardly new, with
the earliest investigations credited to the Nobel Prize-winning embryologist Elie Metchnikoff over
a century ago. Metchnikoff posited that our microbial inhabitants released toxins that would lead
to host damage [2]. In probably the earliest example of targeted probiotic therapy, he introduced
Bacillus bulgaricus to individuals to mitigate the production of these harmful toxins. Another early
pioneer in this area was Yale bacteriologist, Leo Rettger who reported in 1920 that the consumption of
Lactobacillus acidophilus could successfully recolonize the human gut as a curative [3]. In this study,
the co-administration of bacteria with certain carbohydrates is perhaps the earliest example of the
combined use of probiotic and prebiotics, known now as synbiotics.
In the early 1990s, with the development of nucleic acid sequencing methods, the interest in the
microbiome was re-invigorated. New methods including the analysis of ribosomal small subunit RNA
gene probes, e.g., 16S ribosomal gene analysis, quickly found their way into the study of the intestinal
environment. Computational methods enabled the determination of the microbial community with
an unprecedented level of detail. However, beyond composition, it must be recognized that much
of the impact of the bacterial community on the host is transmitted through the metabolites that are
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produced. Microbes produce or transform a wide range of circulating chemicals including amino acids,
fatty acids, bile acids, hormones and vitamins [4,5].
The link between microbial community composition and metabolic activity is indirect and has been
shown to be strongly influenced by functional redundancy and metabolic plasticity [6–8]. Functional
redundancy indicates that some species can be interchangeable, while enacting similar functions. Thus,
differences in microbial communities may not lead to differences in function. Metabolic plasticity
reflects the ability of a given community to adapt to environmental changes by adjusting metabolic
functioning. In order to better understand the ways in which probiotic and prebiotic interventions
influence the host, analysis of the microbial community should also be accompanied by analysis of the
function of these communities by examining the metabolome.
Experimental models on the use of probiotics and prebiotics have provided a detailed foundation
on the physiological impact of these interventions. Murine studies have included investigations into
diabetes, neurodevelopmental disorders, non-alcoholic steatohepatitis and more [9–11]. An especially
noteworthy model approach involves the use of germ-free or gnotobiotic mice. The latter typically
refers to mice that are hosts to a specifically defined microbiota. In one of the earliest examples of this
type of study, fecal samples from obese patients were transplanted into germ-free mice which lead to an
accumulation of body fat [12]. This study set the stage for further studies in these models to study the
impact of probiotics and prebiotics. In the study by Martin et al., the ability of probiotics and prebiotics
to impact the fecal metabolome was evaluated in three sets of mice with three distinct microbiota
compositions [13]. The first set had a conventional (i.e., wild-type) microbiota. The second group was
“conventionalized,” wherein germ-free mice were removed from their sterile incubators and place in
normal cages. The last group were germ-free mice that were inoculated with human baby microbiota
(HBM). All mice in the HBM group were supplemented with Lactobacillus paracasei and some of this
group also received a prebiotic composed of galactooligosaccharides. Metabolomics analysis using
1H NMR revealed that the metabolome of the conventional and conventionalized quickly converged
and were distinct from the HBM groups. Furthermore, the HBM group receiving only the probiotic
was distinct from the group that received both the probiotic and prebiotic. This study leveraged the
tremendous level of control available in mouse models to demonstrate how the fecal metabolome can
provide unique information on nutrient-microbiota relationships.
The ultimate goal of much of the research on probiotics and prebiotics is to aide in the design of
more effective and personalized interventions to improve human health. Unfortunately, the exquisite
level of control available in animal studies including rigorously controlled diets and environments,
strictly defined probiotic and prebiotic dosing schedules and the opportunity for invasive sampling
are not available in humans. The focus of this review is to evaluate the current state of the science in
analyzing the effects of probiotics and prebiotics in the context of human clinical trials. These studies
will be evaluated to understand the challenges in study design, analytical approaches and interpretation.
Furthermore, the focus will only include those studies which employed a discovery-based metabolomics
approach to more completely interrogate the action of prebiotics and probiotics on human health.
The studies that met the focused criteria were found in PubMed using the search string (microbiome
OR microbiota) AND (metabolomics OR “metabolite profiling” or “metabolic profiling”) AND
(probiotics OR prebiotics). Careful review yielded 15 studies that reported results from some form
of human clinical trial and included a discovery-based metabolomics approach. These studies were
found to focus on five main areas of health and the results of these studies will be described below.
Details of each of these studies are presented in Figure 1.
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effects of inulin-type fructans in a randomized, double-blind, placebo-controlled, crossover trial [14]. 
In this study, 44 healthy volunteers had a two-week run-in phase, followed by a four-week 
intervention, two-week washout and then crossover.  
The prebiotic intervention was composed of daily consumption of chicory derived inulin. 
Microbial community analysis was carried out using 16S rDNA gene sequencing. The results showed 
that there were significant alterations in the microbiota with inulin consumption. In particular, there 
was an increase in Bifidobacteria and Anaerostipes, along with a decrease in Bilophilia. The increase in 
Bifidobacterium was expected as the prebiotic concept actually emerged from the observation of 
selective stimulation of Bifidobacterium with inulin fermentation [1]. The metabolomics analysis 
utilized a GC/MS platform and was designed to only focus on the volatile organic compounds per 
the method of De Preter et al. [15]. This provided a significantly limited picture of the fecal 
metabolome, leaving out essentially all polar compounds including important organic acids such as 
lactate, succinate and formate. The cross-over analysis revealed one metabolite, dodecanal, which 
increased with inulin consumption. Dodecanal may be of dietary origin [16], but it may also be the 
result of altered intestinal lipid digestion [17]. 
The second study examined the prebiotic effects of wheat bran extracts (WBEs) on the microbial 
community and metabolome [18]. In addition to looking for alterations in the fecal microbiota and 
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Figure 1. escription of hu an clinical studies of probiotic and prebiotic interventions that included
the use of a discovery-based etabolo ics analysis. Abbreviations: R, rando ized; DB, double blind;
PC, placebo controlled; CT, clinical trial.
2. Effects on Healthy Subjects
One of the main questions regarding prebiotic and probiotic interventions is how much they can
influence the community and function of a healthy gut. The study by Vandeputte et al. examined the
effects of inulin-type fructans in a randomized, double-blind, placebo-controlled, crossover trial [14]. In
this study, 44 healthy volunteers had a two-week run-in phase, followed by a four-week intervention,
two-week washout and then crossover.
The prebiotic intervention was composed of daily consumption of chicory derived inulin. Microbial
community analysis was carried out using 16S rDNA gene sequencing. The results showed that
there were significant alterations in the microbiota with inulin consumption. In particular, there
was an increase in Bifidobacteria and Anaerostipes, along with a decrease in Bilophilia. The increase
in Bifidobacterium was expected as the prebiotic concept actually emerged from the observation of
selective stimulation of Bifidobacterium with inulin fermentation [1]. The metabolomics analysis utilized
a GC/MS platform and was designed to only focus on the volatile organic compounds per the method
of De Preter et al. [15]. This provided a significantly limited picture of the fecal metabolome, leaving
out essentially all polar compounds including important organic acids such as lactate, succinate and
formate. The cross-over analysis revealed one metabolite, dodecanal, which increased with inulin
consumption. Dodecanal may be of dietary origin [16], but it may also be the result of altered intestinal
lipid digestion [17].
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The second study examined the prebiotic effects of wheat bran extracts (WBEs) on the microbial
community and metabolome [18]. In addition to looking for alterations in the fecal microbiota
and metabolome, this study examined the potential of this prebiotic intervention to impact risk
markers for colorectal cancer. The study included 20 healthy subjects in a randomized, double-blind,
placebo-controlled, crossover trial. Each subject consumed the wheat bran prebiotic or maltodextrin
control for 3 weeks separated by a three-week washout period. Gut microbiota composition was
measured by denaturing gradient gel electrophoresis, along with real-time PCR, and untargeted
metabolomic analysis was carried out with a GC/MS platform. The colorectal cancer risk was evaluated
using the comet assay to measure fecal water genotoxicity, as described by Wasson et al. [19].
The metabolomics analysis provided relative quantification on a total of 285 different metabolites
with an average of 91 metabolites per sample. To provide more quantitative results of the short-chain
fatty acid, 2-ethylbutyric acid, was used as an internal standard. Multivariate analysis using partial
least squares discriminant analysis (PLS-DA) suggested that wheat bran intake was associated with
higher levels of cycloalkenes, alcohols, and esters, but no individual metabolites met a threshold
for significance.
Although the fecal water cytotoxicity and genotoxicity assays did not reveal a statistically
significant difference between the prebiotic intervention and placebo, a PLS-DA showed that metabolite
profiles were clustered based on the degree of cytotoxicity or genotoxicity of the samples. The analysis
showed that acids, alcohols, and esters were associated with greater cytotoxicity, while cycloalkanes
and a set of terpines including α-pinene, α- and β-phellandrene, limonene, 3-carene and camphene
were associated with low toxicity. Terpines are secondary metabolites produced by plants and have
been shown to have antioxidant and antimicrobial effects [20]. Another interesting metabolomic
finding was a reduction in isovaleric acid with WBEs. This branched chain fatty acid is a marker
protein fermentation which suggests that WBEs may alter the colonic fermentation pattern to be more
saccharolytic rather than proteolytic.
During the aging process, alterations in the immune system have been observed and recent studies
have shown that the microbiota and the microbial metabolome can impact certain immunological
functions [21]. In the study by Vulevic et al., a prebiotic intervention using a galactooligoscaccharide
(GOS) mixture was given to a cohort of elderly patients to observed the impact on the gut microbiota,
fecal metabolome and immunological functions [22]. The study involved forty healthy patients
between the ages of 65 and 80 in a randomized, double-blind, placebo-controlled, cross-over trial.
The study design included ten-week interventions separated by a four-week wash-out. The GOS
intervention was found to have immunomodulatory effects including alterations in NK cells and several
cytokines, including an increase in Il-10 and a decrease in IL-1β. Principal changes in the microbiota
were evaluated using fluorescence in situ hybridization. The main alteration included increases in
Bifidobacteria and Bacteroides. The metabolomics analysis was carried out using 1H NMR and found
that the increased levels of Bifidobacterium were correlated to an elevation in the fecal concentrations in
lactate, glutamate, ornithine and caproic acid. As lactate is product of Bifidobacerium metabolism, this
result supports the prebiotic simulation of that bacterium. The changes in glutamate and ornithine
are likely associated with changes in the diet. Diet records did not indicate any differences in protein
intake between the treatment groups, but when correlating Bifidobacterium levels with protein intake
across all subjects, the levels of protein consumption were higher in those with higher Bifidobacterium
levels. The metabolomics data in this study supported the use of prebiotics to alter both the level and
function of Bifidobacterium and also demonstrated how metabolomics analysis can reveal additional
insights into the effects of dietary patterns in the study.
3. Overweight/Obesity
The first associations between the gut microbiota and obesity were reported by Turnbaugh et
al. in studies using fecal transplants from obese humans into germ-free mice [12]. When implanted
with the “obese microbiota”, the mice experienced significantly greater increases in body fat than
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when implanted with the “lean microbiota”. Given the global health burden of obesity, there is a
great interest in finding ways to manipulate the gut microbiota as a treatment for obesity. The search
parameters found two studies where prebiotics or probiotics were evaluated in human studies of
obesity using metabolomics.
In a study of obese women, the effects of inulin-type fructans (ITFs) was examined to
evaluate the effects on gut microbial composition and systemic metabolism [23]. This double-blind,
placebo-controlled intervention involved 30 obese women treated daily with an ITF supplement
for three months. 1H NMR analysis of urine and serum revealed several interesting correlations
between metabolite changes and gut bacteria. The levels of Propionibacterium and Bacteroides vulgatus
were both decreased by the prebiotic treatment and correlated with decreased plasma levels of
phosphatidylcholine and lactate. The levels of these bacteria and metabolites also appear to be
associated with lower adiposity. An increase in the levels of Collinsella, a genus of Actinobacteria was
observed in the prebiotic group and was correlated to the levels of urinary hippurate. In contrast to
most studies which focused on the fecal metabolome, this study examined urine and serum and found
several novel correlations between the gut microbiota and systemic metabolite levels.
Hibbert et al. reported a study involving both probiotic and prebiotic interventions in a
randomized, double-blind, placebo-controlled trial of 134 overweight adults [24]. This study included
four treatment groups (1) placebo (microcrystalline cellulose) (2) treatment with the prebiotic Litesse
Ultra® polydextrose (LU), (3) Bifidobacterium animalis subsp. Lactis 420® (B420) and (4) LU + B420, with
the intervention lasting six months. The fecal metabolome was analyzed by 1H NMR and serum bile
acids were measured using UPLC/MS/MS as described by Han et al. [25]. The results showed that the
gut microbiota was modified for all of the groups with the LU intervention showing a stronger effect
than B420 alone. The abundance of the family Christensenellaceae was highly elevated in the groups
treated with LU alone and in combination with B420. These levels were also positively correlated with
the fecal branched chain fatty acids (BCFAs), isobutyric acid, isovaleric acid, 2-methylbutyric acid
and 3-methyl-2-oxovalerate and the plasma bile acids, lithocholic acid and hyodeoxycholic acid. The
BCFAs are typically generated by microbial fermentation of undigested proteins in the colon, but it has
been shown that these metabolites can be derived from polydextrose consumption [26]. A recent study
has shown that BCFAs affect human adipocyte lipid and glucose metabolism by inhibiting de novo
lipogenesis [27]. In this study, the combined results of microbial community analysis and metabolomics
provide new insights on how these interventions may affect host energy metabolism.
4. Infant and Pediatric Health
The composition of the infant gut microbiota has been shown to be dramatically influenced
by dietary factors [28,29]. Clear differences in the trajectory of microbial community development
have been shown between breastfed and formula-fed infants [30,31]. The study by Bazanella et al.
was designed to evaluate the effects of a probiotic-supplemented formula intervention on the
composition and function of the infant gut over the first year of life [32]. In this randomized,
double-blind, placebo-controlled, clinical trial new-born infants were fed a standard whey-based
formula supplemented with Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum and
Bifidobacterium longum subspeces infantus or a control formula with no supplements. Breastfed controls
were also included in the analysis. The cohort was composed of 49 infants in the control group and 48
infants in the intervention. Diversity and composition of the fecal microbiota were determined by 16S
rRNA sequencing and the fecal metabolome was analyzed by UPLC/MS. Infants in the intervention
group showed decreased numbers of Bacteroides and Blautia, along with alterations in lipids and
unknown metabolites at one month. Over the remainder of the study period, the microbiota composition
and metabolome converged. Significant differences were observed between breast fed and formula
fed infants with the major discriminating metabolites assigned to sterol lipids, glycerophospholipids
and fatty acids. A targeted short-chain fatty acid analysis could also distinguish breast from formula
Metabolites 2020, 10, 120 6 of 14
fed infants with breast fed infants having lower proportions of propionate, butyrate, valerate and
isovalerate, while formula fed infants had higher amounts of pyruvic acid and lactic acid.
Infantile colic is a condition experienced by somewhere between 10% and 40% of infants and is
characterized by extended periods of inconsolable crying [33]. It is considered to be a gastrointestinal
disorder, but the etiology remains unknown. Several studies have suggested that alterations in the
infant gut microbiota could be contributing to this condition [34]. In the study by Baldassarre et al., a
multi-strain probiotic supplement was used to treat infantile colic [35]. This randomized, double-blind,
placebo-controlled, clinical trial involved daily oral probiotic treatment for 21 days. Microbial analysis
with qPCR and metabolomics analysis with 1H NMR was carried out on 8 subjects from the placebo
group and 11 from the probiotics group. The probiotic group experienced a significant decrease in
minutes of crying per day at days 14 and 21 of the study. Interestingly, no significant changes in the
composition of the microbiota were found over the course of the study, but 16 metabolites were found
to be significantly different at day 21 between the placebo and probiotics groups. An interesting set of
metabolites including the amino acids alanine, leucine, and isoleucine, along with the organic acids,
2-hydroxyisovalerate and 2-oxoisocaproate, were altered, suggesting a significant change in branched
chain amino acid metabolism with the probiotic.
Recurrent respiratory tract infections (RRIs) are a common occurrence in preschool age children.
Pidotimod is an immunostimulant that is used to treat RRIs in children. A recent metabolomics study
of children with RRIs taking Pidotimod showed that the drug can partially restore the metabolic
alterations induced by RRIs, but some of the microbiota derived metabolites remained altered [36]. In
the follow-up study by Santamaria et al., a randomized, double-blind, placebo-controlled trial was
conducted to determine if Pidotimod and/or a Bifidobacteria probiotic can reduce the morbidity of RRIs
and alter the urinary metabolomics profiles in preschool children [37]. A cohort of children age 3–6
were randomly assigned to the four groups where subjects received treatments for the first 10 days of
each month for four months. The primary clinical endpoint was the number of symptom free days.
Children receiving Pidotimod either with or without probiotic had significantly more symptom free
days. Metabolic profiles were measured on 25 patients using UPLC/MS. No significant differences in
the metabolic profiles were observed between the placebo and probiotic group, but a large number
were observed between the placebo and Pidotimod both with and without probiotic. Using a shared
and unique structures plot they found that steroid hormones, metabolites derived from the vitamin B
pathway and some amino acids were associated with the use of Pidotimod. At the extremes of this type
of plot are the metabolites that can be related to an interactive effect of Pidotimod and the probiotic.
These included methylhippuric acid, kynurenine, deoxycholic acid 3-glucuronide, and oxoglutaric acid.
This set of metabolites are associated with a number of different aspects of gut microbial metabolism
including tryptophan and bile acid metabolism. However, this pattern cannot be due specifically to
the effects of the probiotic as these alterations were only observed when Pidotimod was administered
with or without the probiotic. Given the clinical outcome, it is suspected that these metabolites are in
some way, associated with increased immune function, but further work is required to elaborate.
Probiotics have been used in a number of studies of pre-term infants with much of the attention
going toward the treatment of necrotizing enterocolitis and late onset sepsis [38]. For the former,
evidence from more than 20 RCTs suggest a positive impact of probiotics [39]. In a study of pre-term
infants, by Abdulkadir et al., 16S rRNA sequencing and LC/MS-based metabolomics were used to
determine the effect of probiotics on pre-term infants in the neonatal intensive care unit (NICU) [40]. The
probiotic consisted of Lactobacillus acidophilus-NCIMB701748 and Bifidobacterium bifidum-ATCC15696
(marketed as Infloran®). Fecal samples were collected before, during, and after probiotic intake from
7 patients and 3 time-matched controls. Samples were also collected following discharge from the NICU.
The bacterial community profiling showed greater abundance of Bifidobacterium and Lactobacillus during
the probiotic treatment compared to controls. After the supplementation stopped the Lactobacillus levels
went down, but the Bifidobacterium concentrations remained high indicating successful colonization.
The biggest difference in the metabolomics profiles was between subject post-discharge compared with
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those in the NICU. This would suggest that exposure to the new environment has a greater impact
on these infants than the probiotic. Unfortunately, specific metabolite assignments were not made in
this study.
5. Irritable Bowel Syndrome
Irritable bowel syndrome is the most common functional bowel disorder and is characterized
by the association of abdominal pain or discomfort, with changes in stool frequency or consistency
without a clear disease etiology [41]. In the study by Hong et al., targeted culture methods were
combined with metabolomics to evaluate the effects of a probiotic yogurt drink on 74 IBS patients [42].
In this randomized, double-blind, placebo-controlled clinical trial subjects consumed the probiotic
yogurt drink three times per day with meals over an eight-week period. The probiotic therapy yielded
positive effects on the symptoms of the patients including pain, flatulence and defecations scores. The
quantitative cell culture methods revealed that Lactobacillus spp. levels were significantly increased
after the eight-week study, while the levels of Bifidobacteria did not change.
NMR-based metabolomics analyses were carried out on both serum and fecal samples. For both
types of samples, no filtration or extraction methods were used so that the samples contained all
of high molecular weight components including proteins and lipoproteins in serum and proteins,
fiber and mucopolysaccharides in feces. Pattern recognition methods including principal components
analysis were carried out on binned spectra. Analysis of the fecal samples suggested no significant
differences between the placebo and probiotic treatment groups. The authors suggest that this is due
to the confounding presence of unidentified metabolite peaks related to individual diets. The biggest
effect found in the serum metabolomics analysis was between males and females. A well-known
difference can be seen in the lipoprotein signatures of males and females in serum NMR spectra [43].
This led to separate analyses of the serum from each gender. No significant effects of the probiotics
were found in the male subjects, but a weak difference in females was found using OPLS-DA. This
analysis revealed increased lactate and reduced glucose and tyrosine levels in the female sera after the
probiotic intervention. The increased lactate is sensible as the probiotic contains fermentative bacteria
that produce lactate. Interestingly, the glucose and tyrosine levels after the probiotic treatment were
very close to those found in the healthy subjects and significantly lower than before treatment. It is
suggested that the reduced serum glucose levels may be the result of a probiotic rescue of impaired
glycolysis in the subjects. A marked increase in serum tyrosine is observed in patients with liver
disease [44] and so the decreased levels of tyrosine is posited to indicate an improvement in liver
function. Hepatobiliary diseases are one of the most common comorbidities of IBD, therefore it is
possible that the probiotic is having some corrective action on mild liver metabolic impairments [45].
This observation of lipoproteins enabled the detection of some potential sex related effects of the
probiotics, but unfortunately the broad baseline features from these macromolecules interferes with the
ability to quantitatively fit the NMR peaks. The spectral profiles were compared using integral binning
which is less quantitative due to the effects of spectral overlap and interfering baseline components.
This analysis approach was also used for the fecal samples. These added sources of variability may
have limited ability to detect significant metabolite differences.
In another study of IBS, Noorbakhsh et al. used NMR-based metabolomics to investigate the
metabolic impact of a synbiotic yogurt treatment on a cohort of diarrhea predominant IBS patients
(IBS-D) [46]. This study examined the serum and urine metabolomes of 16 healthy and eight IBS-D
patients before and after a four-week synbiotic yogurt intervention. The yogurt was cultured with
L. plantarum and L. fermentum and contained xylooligosaccharides as a prebiotic. Fecal samples were
cultured before and after the intervention. It was found that the number of viable fecal Lactobacilli
from IBS-D patients was significantly lower at baseline than controls and increased significantly after
the intervention. No differences were found in the control group before and after the intervention.
Serum NMR showed several significant differences between the IBS-D and control groups before the
intervention, including elevated levels of acetoacetate, myo-inositol and sarcosine, along with reduced
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levels of threonine and methionine. Comparing the serum metabolome of the IBS-D groups before and
after the intervention revealed a decrease in acetone and an increase in the concentrations of choline,
phenylalanine and the three branched chain amino acids, leucine, isoleucine and valine.
Several of the metabolites that distinguish between the healthy and IBS-D subjects point to
alterations in one-carbon metabolism including serum methionine and sarcosine and urinary taurine.
This led the authors to utilize an ELISA based assay to measure another key intermediate in the
one-carbon pathway, homocysteine. The serum levels of homocysteine were found to be increased
levels in the IBS-D group. After the intervention, the levels were reduced further suggesting that one
mechanism by which the synbiotic treatment improves IBS-D symptoms may be through modulation
of one-carbon metabolism.
6. Women’s Health/Pregnancy
The vaginal microbiota is part of a complex antimicrobial defense system that protects women
against disease [47]. In the healthy state, the vaginal microbiota is dominated by the Lactobacillus
genus [48]. It is thought that the lactate produced by these bacteria creates an acidic environment that
restricts the growth of many pathogenic bacteria. The premenopausal vaginal microbiota has been
shown to be highly dynamic compared with the post-menopausal state, likely due to the effects of
hormone cycling. In the study by Bisanz et al., a detailed examination of the effects of a probiotic
treatment on the post-menopausal vaginal microbiome was conducted [49]. In this study, seven
subjects received vaginal administration of a probiotic composed of L. rhamnosis GR-1 and L. reuteri
RC-14 and seven received a placebo treatment. The women were evaluated using the Nugent scoring
system which is used to assess bacterial vaginosis (BV). All women in the study had intermediate
scores indicative of a potential risk of transition to BV. The three-day treatment did not impact the
Nugent score, but some changes in the microbial community were observed. Analysis with 16S rRNA
sequencing revealed an increase in the relative abundance of Lactobacillus. An untargeted GC/MS
analysis was conducted, but no differences were found between subjects on the probiotic and placebo.
Obtaining a sufficient amount of sample for metabolomics was noted as a challenge using vaginal
swabs and samples from only four women who demonstrated an increase in Lactobacilli were analyzed.
A significant positive correlation between the lactate levels and the amount of lactate producing
bacteria was found. The authors recognized this might seem to be an intuitive finding, but not that to
their knowledge, this correlation had not yet been reported.
The next study of the use of probiotics on the vaginal microbiota, also conducted by the Reid Lab,
evaluated the use of oral probiotics use in pregnant women in Rwanda [50]. The use of probiotics is
not well established in developing counties like Rwanda, but the potential for treating and preventing
may of the diseases that plague these countries like urogenital, diarrheal and respiratory diseases is
very high [51–53]. In this randomized, blinded, placebo-controlled clinical trial, a total of 31 women
completed the study (13 placebo, 18 probiotic), receiving daily oral supplements for one month. Vaginal
swabs were used to collect samples for 16S rRNA sequencing and GC/MS based metabolomics.
The results showed the expected low bacterial diversity associated with a healthy vagina. No
significant changes in the vaginal microbiota composition was observed between the placebo and
probiotic treatment. Similarly, no significant changes were observed in the vaginal metabolome.
Interestingly, women in the placebo group were significantly more likely to give birth preterm with
three women in the placebo group compared with none in the probiotic group. Given the small size
of this study, this intriguing finding will have to be validated in a larger cohort. Further analysis of
the metabolomics data confirmed a previously observed set of biomarkers associated with bacterial
diversity and bacterial vaginosis [54]. High levels of 2-hydroxyisovalerate and γ-hydroxybutyrate,
both produced by Lactobacillus crispatis and BV-associated anaerobes were significantly higher in
subjects with a high Nugent score.
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7. Other Studies
The search criteria found studies in two areas for which there was only one example. The first was
a study by Tankou et al. on the effects of a probiotic supplementation on relapsing remitting multiple
sclerosis (MS) [55]. The gut microbiome has been implicated in several autoimmune disorders including
MS, along with rheumatoid arthritis and inflammatory bowel disease [56–59]. In this study, nine MS
patients and 13 healthy controls received a multi-strain probiotic containing Lactobacillus, Bifidobacteria
and Streptococcus twice daily for 2 months. The study demonstrated that the probiotic increased the
abundance of several taxa known to be depleted in MS such as Lactobacillus. Other taxa previously
associated with dysbiosis in MS including Akkermansia and Blautia were found to be decreased with the
probiotic further demonstrating the beneficial effects. Peripheral blood mononuclear cells (PBMC) were
collected and gene expression studies showed a decrease in expression of a number of proinflammatory
genes following probiotic administration. Correlation of the metabolomics with 16S rRNA sequencing
data revealed a positive association between the Lactobacillus OUT 304,724 and the fecal hypoxanthine
level. This metabolite also demonstrated a negative association with the decreased expression of the
MS risk alleles HLA.DPB1 and HLD.DPA1 in PBMCs.
The use of a probiotic supplement in a study of atopic dermatitis in adults was reported by
Matsumoto et al. [60]. Atopic dermatitis, also referred to as eczema, is a skin condition characterized by
red and itchy skin. There is an increasing body of evidence that the gut microbiota plays a significant
role in this disorder [61–64]. In this randomized, double-blind, placebo-controlled clinical study,
44 patients received a probiotic supplement containing B. animalis subsp lactis LKM512 or placebo
daily for 8 weeks. The probiotic provided a significant benefit to the patients as evaluated by reduced
itching and dermatology-specific quality of life scores. Real-time PCR confirmed that the patients
on probiotics had increased fecal levels of B. animalis subsp lactis LKM512. The fecal metabolomics
from three patients who experienced dramatic improvement in their symptoms with the probiotics
revealed a significant increase in kynurenic acid. Increased levels of this metabolite were also shown to
be negatively associated with itching symptoms.
A previous study by this group on a similar cohort of adults with atopic dermatis found that
consumption of a probiotic LKM512 yogurt for only four weeks lead a similar improvement in
symptoms [65]. In this study, they performed HPLC analyses of fecal polyamines and short-chain fatty
acids. These metabolites were targeted due to their association with the maintenance and maturation
of intestinal mucosal barrier function which has been shown to weakened in AD patients [66–72]. It is
interesting to note that none of these metabolites were found to be significantly altered when profiled
in the untargeted manner using the LC/MS method.
8. Discussion and Conclusions
With the increasing interest in the use of prebiotic and probiotic interventions for a wide range of
diseases, it is becoming more and more important to understand the detailed biochemical mechanisms
through which they function. As discussed earlier, analysis of the microbial community structure using
gene sequencing methods may not provide information on the actual functioning of the bacteria. Despite
a plethora of pre-clinical studies, there have been relatively few studies of the use of probiotics and
prebiotics in the context of human clinical trials that have taken advantage of advanced metabolomics
approaches. The examples presented here cover a range of features including pathological condition,
cohort size, dosing frequency and duration. The intent of this review was to evaluate how these studies
were designed and analyzed and consider ways in which future studies could be optimized.
A review of the study designs of the clinical trials described here shows one important variable
that was generally not interrogated. As stated in the definition of probiotics and prebiotics, these
therapies need to be “administered in adequate amounts” in order to provide the beneficial effects to
the host. In the studies described, the dose, frequency and duration of the interventions were set at
the beginning of the study and no clear indications of how these parameters were derived was given.
Defining the dosing for a pharmaceutical involves a dose–response study with the guiding principal of
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“start low, go slow”. As probiotics and prebiotics are generally regarded as safe, such dose–response
studies would hold far less risk than with a pharmaceutical. The obvious challenge with dose-range
studies is that they will require larger numbers of patients to evaluate the effects of dosing, frequency
and duration, but at some point, these types of studies will have to be carried out. The most practical
applications might be in well-defined cohorts, e.g., patients with a specified pathology. In this way, the
outcome phenotype should be strong enough that smaller cohorts may still have the statistical power
to determine the effective dosing strategy.
As with any metabolomics analysis, there are a number of analytical sources of variation that need
to be considered. The range of analytical platforms used in the studies discussed here are representative
of the rest of the metabolomics field. The advantages and disadvantages of these platforms has been
extensively reviewed and a summary of the different platforms used in fecal metabolome analysis is
presented in the review by Karu et al. [73,74]. Given the strengths and weaknesses of each platform,
especially in terms of sensitivity, quantitation and reproducibility, the use of multiple platforms
would be highly advantageous. Examples of this were seen in several of the studies presented where
global, untargeted analyses were combined with targeted metabolomics to provide more quantitative
measurements of important metabolites such as short-chain fatty acids that may be missed by the
primary untargeted approach.
A challenge that is specific to metabolomics of fecal samples is the stabilization of the fecal
metabolome. In studying the serum metabolome, the protocol requires that the serum be quickly
separated from the metabolically active red blood cells. Similarly, the fecal metabolites need to be
protected from continued metabolism by the biologically active bacteria. Rapid freezing at −4 ◦C or
lower as well as storage in 95% ethanol have been shown to have provide sufficient protection against
continued metabolism [75]. In human studies, especially when the samples are collected at home and
then delivered to the clinic, there will almost certainly be some alterations in the metabolome occurring
during that time period. This additional source of variation may limit the observation of significant
results where many studies will have small effect sizes. In the future, more rapid and robust means of
stabilization that do not interfere with the metabolomic profiling are needed.
Another source of variation in fecal samples is the water content. Fecal samples typically contain
60%–85% water, depending upon fiber intake [76]. This variability is less than typically found in urine
samples but is still significant when searching for potentially small metabolite changes. As with urine
samples, there are data processing methods that will help minimize these effects. The use of “constant
sum normalization,” where the total spectral area for NMR and total ion count for MS is set to a selected
value, is often used. Probabilistic quotient normalization is another post-processing normalization
method that has been used to account for variability in fecal composition [77]. Alternatively, data can
be collected on lyophilized samples, but this can affect metabolite composition. Interestingly, in most
of the studies discussed, little detail on the application of normalization methods was included, which
may have reduced the information content of the studies.
The studies reviewed here demonstrate the potential of metabolomics to contribute to the
understanding of how prebiotics and probiotics function in humans. Continued work on the
development of standardized protocols for fecal metabolomics will help minimize both the biological
and analytical sources of variation. These developments, along with the use of multi-platform
approaches, will provide more detailed and comprehensive metabolomics data. Combining this data
with advanced microbial sequencing analyses will help elucidate the detailed biochemical mechanisms
by which probiotics and prebiotics can be optimally applied to improve human health.
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